WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

HALO past earnings growth

How has HALO's earnings growth performed historically?
Company
43.92%
Industry
54.16%
Market
72.61%
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HALO's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HALO past revenue growth

How has HALO's revenue growth performed historically?
Company
25.62%
Industry
144.63%
Market
17.55%
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HALO's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

HALO earnings and revenue history

Current Revenue
$829.3M
Current Earnings
$281.6M
Current Profit Margin
34%

HALO Return on Equity

Current Company
204.8%
Current Industry
-63.5%
Current Market
188%
HALO's Return on Equity (204.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when HALO announces earnings.

HALO Return on Assets

Current Company
15.8%
Current Industry
2.9%
HALO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

HALO Return on Capital Employed

Current Company
22.65%
Current Industry
19.5%
HALO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HALO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
HALO$829.25M$451.95M$281.59M+40.43%+107.49%
IBRX$622.00k-$429.41M-$583.20M+67.62%N/A
KRYS$50.70M$17.90M$10.93MN/AN/A
BBIO$9.30M-$551.39M-$643.20M-30.80%N/A
CRSP$371.21M-$130.89M-$153.61M+160.00%N/A
View Top Biotech Stocks

HALO earnings dates

Next earnings date
May 7, 2024

Halozyme Therapeutics Earnings & Revenue FAQ

What were HALO's earnings last quarter?

On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q4 2023 earnings per share (EPS) of $0.65, up 51.16% year over year. Total Halozyme Therapeutics earnings for the quarter were $85.39 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $0.43.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

What was HALO's earnings growth in the past year?

As of Q2 2024, Halozyme Therapeutics's earnings has grown 43.92% year over year. This is 10.24 percentage points lower than the US Biotechnology industry earnings growth rate of 54.16%. Halozyme Therapeutics's earnings in the past year totalled $281.59 million.

What is HALO's earnings date?

Halozyme Therapeutics's earnings date is Invalid Date. Add HALO to your watchlist to be reminded of HALO's next earnings announcement.

What was HALO's revenue last quarter?

On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q4 2023 revenue of $230.04 million up 26.75% year over year. In the same quarter last year, Halozyme Therapeutics's revenue was $181.50 million.

What was HALO's revenue growth in the past year?

As of Q2 2024, Halozyme Therapeutics's revenue has grown 25.62% year over year. This is 119.01 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Halozyme Therapeutics's revenue in the past year totalled $829.25 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.